John Miller
Corporate Officer/Principal presso JAZZ PHARMACEUTICALS PLC
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Bruce Cozadd | M | 60 | 21 anni | |
| Renée Galá | F | 52 | 4 anni | |
| Seamus Mulligan | M | 63 | 12 anni | |
| Mark Smith | M | 72 | 4 anni | |
| Anne O’Riordan | F | 56 | 5 anni | |
| Patricia Carr | F | 53 | 12 anni | |
| Norbert Riedel | M | 66 | 11 anni | |
| Catherine Sohn | M | 71 | 12 anni | |
| Jennifer Cook | F | 58 | 4 anni | |
| Heather McSharry | F | 62 | 11 anni | |
| Rick Winningham | M | 64 | 14 anni | |
| Ken O'Keefe | M | 57 | 20 anni | |
| Peter Gray | M | 69 | 11 anni | |
| Patrick Enright | M | 62 | 15 anni | |
| Robert Iannone | M | 57 | 5 anni | |
| Andrea N. Flynn | M | - | - | |
| Aislinn Doody | M | - | - | |
| Neena Patil | F | 49 | 5 anni | |
| Heidi Manna | F | 53 | 6 anni | |
| Shawn Mindus | M | - | - | |
| Kristin Bhavnani | F | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Robert A. Heft | M | 69 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 7 anni |
| Eric Trachtenberg | M | 51 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 anni |
| Ted Harding | M | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 2 anni |
| Fredric D. Price | M | 78 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 6 anni |
| Thomas Schuetz | M | 63 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 5 anni |
| Mary Reumuth | F | 48 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 anni |
| Mittie Doyle | M | 59 | 3 anni | |
| Rebecca Velez Frey | F | - | 5 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Irlanda | 21 | 72.41% |
| Canada | 6 | 20.69% |
| Stati Uniti | 3 | 10.34% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- John Miller
- Contatti personali
